PlasmaGen Biosciences has raised Rs 150 crore in a fresh funding round led by ViNS Bioproducts, marking a significant step in the company’s growth trajectory and valuing it at over Rs 1,500 crore.
The Bengaluru‑based plasma biopharmaceutical company secured the investment with participation from high‑net‑worth individuals, family offices, pharmaceutical entrepreneurs, and existing investors, adding to more than Rs 600 crore it has raised since its founding in 2010.
PlasmaGen develops and manufactures blood plasma‑derived therapies, supplying hospitals and healthcare programmes across India. The fresh capital is intended to support international expansion, broaden the company’s product portfolio, and strengthen manufacturing and leadership capabilities to achieve strategic growth objectives.
The company’s plasma fractionation facility in Kolar, Karnataka, which began commercial operations in 2024, is among a limited number of specialised facilities in India and has contributed to recent revenue growth.
The funding positions PlasmaGen to accelerate its growth plans, expand access to life‑saving plasma therapies, and reinforce its presence in both domestic and international biopharmaceutical markets.
